Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick - 2Zelensky names spy chief to head presidential office after corruption row
- 3Pick Your Top Method for starting the Morning
- 4Surf Spot Mechanics: Bells Beach
- 5Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how
- Ancient Pompeii construction site reveals the process for creating Roman concrete
- Heat Wave Fuels Massive Wildfire In Australia
- Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business
- Phonetic Associations: A Survey of \Interfacing Worldwide People group\ Language Trade Application
- What to expect from the planets in 2026 — key dates and sky events
- Choosing the Ideal Bed for Quality Rest and Solace
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- Solid Living Tips: Experiences from a Wellness Fan
